Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943004 · ClinicalTrials.gov registry record · Phase 1
Trial of DFP-14927 in Advanced Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, sponsored by Delta-Fly Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT03943004 is a Phase 1 study of Cancer and Solid Tumor that is actively recruiting participants, run by Delta-Fly Pharma. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03943004, a Phase 1 study of Cancer and Solid Tumor, is actively recruiting participants, sponsored by Delta-Fly Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
Conditions Studied
Interventions
- DRUG DFP-14927
Study Locations (2)
California
- UCLA Department of Medicine- Hematology/Oncology - Los Angeles
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943004
The ClinicalTrials.gov registry entry for NCT03943004 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Delta-Fly Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which DFP-14927 is the first listed.
NCT03943004 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT03943004 about?
NCT03943004 is a clinical study titled "Trial of DFP-14927 in Advanced Solid Tumors". This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
What is the current status of trial NCT03943004?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-09-30. Estimated completion is 2026-06-01.
What conditions does trial NCT03943004 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor.
What interventions are being tested in trial NCT03943004?
The interventions under investigation include: DFP-14927 (DRUG).
Who is sponsoring clinical trial NCT03943004?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943004 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.